Agreements reached under this partnership
Joint Research- 1
CiRA will be responsible for producing neural spheroids and brain organoids and detecting electrical activity using a measurement system with an electrode array.
- 2
The company will be responsible for developing software and data-linkage algorithms for operating virtual organisms and objects in a digital space.
- 3
Incorporate response data obtained from simple electrical stimulation of neural spheroids and brain organoids into LLM prompts.
- 4
Applications and commercialization in the medical and drug-discovery fields and the conversational AI field are envisaged using the foundational technologies for which the company and CiRA have filed patent applications.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact on financial results for the fiscal year ending January 2027 is currently expected to be minor.
| Item | Details |
|---|---|
| Name of alliance partner | Institute for iPS Cell Research and Application (CiRA), National University Corporation Kyoto University, National University Corporation Kyoto University |
| Alliance partner's business activities | Production of neural spheroids and brain organoids from iPS cells, and detection of electrical activity using a measurement system with an electrode array |
| Alliance partner's location | Kyoto, Kyoto Prefecture |
| Type of alliance | Joint Research |
| Details of the alliance | CiRA will be responsible for producing neural spheroids and brain organoids and detecting electrical activity using a measurement system with an electrode array., The company will be responsible for developing software and data-linkage algorithms for operating virtual organisms and objects in a digital space., Incorporate response data obtained from simple electrical stimulation of neural spheroids and brain organoids into LLM prompts., Applications and commercialization in the medical and drug-discovery fields and the conversational AI field are envisaged using the foundational technologies for which the company and CiRA have filed patent applications. |
| Alliance start date | July 2024 (start of joint research) |
| Impact on Business Performance | The impact on financial results for the fiscal year ending January 2027 is currently expected to be minor. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.CiRA aims to score and quantify interactions with iPS cells for applications including pathological analysis of diseases and drug-discovery screening for central nervous system diseases. The company aims to incorporate biological fluctuations into AI and build foundational technology for autonomous AI with a sense of life and emotional fluctuations.